BrainCells

BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It has developed compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment-resistant depression (TRD), and potentially Alzheimer's disease (AD). The company’s products include BCI-838 and BCI-632, which increase synaptic glutamate by inhibiting mGlu2/3 autoreceptors. The company has also established a series of clinical-stage programs to address unmet medical needs in treating mood disorders, psychosis, cognitive impairments, brain repair syndromes, and other CNS diseases.